Insights & news

Van Bael & Bellis launches a series of webinars on: "Brexit and Practical implications of the UK independently flexing its regulatory muscles"

  • 18/11/2020
  • News

Van Bael & Bellis announces today that it will present a series of webinars on "Brexit and Practical implications of the UK independently flexing its regulatory muscles".

In this series of short webinars our UK and EU experts will explore the likely direction and practical impact of UK competition and trade regulation following the UK’s exit from the EU. We trust that you will find these seminars useful to learn more about the UK’s future regulatory landscape, to calibrate your organisation’s Brexit related strategy and to navigate challenges during the UK’s transitioning and beyond.

The programme is as follows:

Tuesday, 3 November                 
13:30 - 14:00 (UK time)
UK competition law enforcement – trends and priorities

Wednesday, 4 November
13:30 - 14:00 (UK time)
The unique UK merger and FDI control regimes   

Tuesday, 10 November                 
13:30 - 14:00 (UK time)
UK competition law enforcement – focus on distribution strategies

Thursday, 12 November
13:30 - 14:00 (UK time)
UK competition law enforcement – focus on life sciences

Tuesday, 17 November
13:30 - 14:00 (UK time)
Brexit and Trade – Customs and FTAs

Thursday, 19 November
13:30 - 14:00 (UK time)
Brexit and Trade – Trade remedies, sanctions and export control

Related insights

Sign up for updates
    • 06/10/2021
    • News

    Alex Stratakis to speak in a panel discussion on Brexit and UK Competition Law

    On 7 October Van Bael & Bellis partner and head of our UK Competition Practice will participate in a panel discussion on "Brexit & Competition law: What Greek/EU lawyers and businesses need to know about the new era of UK competition law". https://lnkd.in/dvyibqgD Other panellists are Dr. Andriani Kalintiri, Lecturer in Competition Law at King's College London. The panel will be moderated by Kyriakos Fountoukakos, Managing Partner, Herbert Smith Freehills in Brussels.

    Read more
    • 19/03/2021
    • Articles

    Brexit - Medicinal Products - Commission Temporarily Redesigns Supply Chains to Cyprus, Ireland, Malta and Northern Ireland

    On 17 March 2021, the Official Journal of the European Union published Commission Delegated Regulation (EU) 2021/457 of 13 January 2021 “amending Delegated Regulation (EU) 2016/161 as regards a derogation from the obligation of wholesalers to decommission the unique identifier of products exported to the United Kingdom” (see, attached copy; the Delegated Regulation). The Delegated Regulation gives effect to a Commission Notice of 23 December 2020 in which the European Commission addressed the issues faced by market operators in Cyprus, Ireland, Malta and Northern Ireland, which are historically dependent on the United Kingdom for their medicine supplies, in complying with the EU’s pharmaceutical acquis following Brexit (see, Van Bael & Bellis Life Sciences News Alert of 23 December 2020). One of the issues identified was that there are currently no importers holding a manufacturing authorisation in Cyprus, Ireland, Malta and Northern Ireland. However, a manufacturing authorisation is required to affix a unique identifier on medicinal products which are imported from outside the EU and placed on the market in the EU. As there are currently no wholesalers in Cyprus, Ireland, Malta and Northern Ireland which can affix a unique identifier on medicinal products that are imported from the United Kingdom, the Delegated Regulation makes it possible for medicinal products which are exported from the EU to the United Kingdom to maintain their initial unique identifier. More precisely, the Delegated Regulation introduces a temporary derogation from the obligation of EU wholesalers to decommission the unique identifier of any medicinal products which they distribute in the United Kingdom. This will facilitate onward distribution of the medicines from the United Kingdom to the cited EU Member States and Northern Ireland. The exemption applies retroactively from 1 January 2021 and will apply until 31 December 2021. The unique identifier was introduced by the Falsified Medicines Directive (Directive 2011/62/EU) with a view to allowing wholesalers and healthcare professionals to verify the authenticity of medicinal products and to identify individual packs.

    Read more
    • 05/03/2021
    • News

    Cross-Border Litigation in the Post-Brexit World: A View from London and Brussels

    Following the UK’s exit from the EU on 31 January 2020 and the end of the transition period under the Withdrawal Agreement, unless proceedings were issued on or before 31 December 2020, the Brussels Recast Regulation no longer applies to questions of jurisdiction and the enforcement of court judgments between the UK and EU Member States. Nothing in the EU-UK Trade and Co-operation Agreement (EU-UK TCA) changes this position. Since the UK has not yet acceded to the 2007 Lugano Convention, issues relating to jurisdiction and the enforcement of judgments as between the UK and EU Member States will be governed by the 2005 Hague Convention on Choice of Court Agreements or, where not applicable, by domestic law (including any relevant bilateral conventions which have been incorporated into domestic law). This Client Alert provides an overview of the new rules applicable to post Brexit cross-border litigation with a particular focus on the impact of such changes in England and in Belgium. It also raises some practical considerations for clients to consider in thinking about cross-border litigation involving the UK and EU Member States. For the benefit of certainty, arbitration may be an attractive option for clients concerned about potential cross-border litigation as between UK and EU parties.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *